

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT mRNA RSV VACCINE (SYS6016) OBTAINS CLINICAL TRIAL APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the mRNA Respiratory Syncytial Virus (RSV) Vaccine (SYS6016) (the “**Product**”), developed by the Group, has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product consists of mRNA molecules encoding the prefusion conformation of the full-length RSV fusion glycoprotein (F-protein), which is encapsulated within lipid nanoparticles. It is indicated for the prevention of lower respiratory tract diseases caused by RSV infections. Preclinical studies demonstrated that the Product translates into the prefusion conformation F-protein in vivo and induces high titers of long-lasting neutralising antibodies. It exhibits good protection against both RSV-A and RSV-B subtype viral strains and has a good safety profile.

RSV can cause respiratory infections in people of all ages, especially children, the elderly, and adults with immunodeficiency or underlying health conditions. These groups are more likely to experience severe infections, respiratory sequelae, and even death, thereby resulting in a significant burden on human health and society. Currently, there is no vaccine available for RSV infections in China, and the Product is at the forefront in the research and development progress in China. The Group will endeavour to advance the clinical research of the Product and strive to market the Product as soon as possible so as to create value for the society and shareholders.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 11 July 2024

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*